JP2019505164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505164A5 JP2019505164A5 JP2018522671A JP2018522671A JP2019505164A5 JP 2019505164 A5 JP2019505164 A5 JP 2019505164A5 JP 2018522671 A JP2018522671 A JP 2018522671A JP 2018522671 A JP2018522671 A JP 2018522671A JP 2019505164 A5 JP2019505164 A5 JP 2019505164A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- host cell
- fucose
- culture
- fucose source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249828P | 2015-11-02 | 2015-11-02 | |
| US62/249,828 | 2015-11-02 | ||
| US201662338280P | 2016-05-18 | 2016-05-18 | |
| US62/338,280 | 2016-05-18 | ||
| PCT/US2016/059922 WO2017079165A1 (en) | 2015-11-02 | 2016-11-01 | Methods of making fucosylated and afucosylated forms of a protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505164A JP2019505164A (ja) | 2019-02-28 |
| JP2019505164A5 true JP2019505164A5 (enExample) | 2019-12-12 |
| JP6983772B2 JP6983772B2 (ja) | 2021-12-17 |
Family
ID=57326491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522671A Active JP6983772B2 (ja) | 2015-11-02 | 2016-11-01 | タンパク質のフコシル化及び脱フコシル化形態の作製方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10975168B2 (enExample) |
| EP (2) | EP3371206B1 (enExample) |
| JP (1) | JP6983772B2 (enExample) |
| KR (2) | KR20250051156A (enExample) |
| CN (2) | CN108431026B (enExample) |
| AU (2) | AU2016350732A1 (enExample) |
| BR (1) | BR112018007356A2 (enExample) |
| CA (1) | CA2999047A1 (enExample) |
| ES (1) | ES2875274T3 (enExample) |
| IL (1) | IL258161B2 (enExample) |
| MX (1) | MX2018004831A (enExample) |
| PL (1) | PL3371206T3 (enExample) |
| SG (2) | SG10202103875WA (enExample) |
| WO (1) | WO2017079165A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108431026B (zh) | 2015-11-02 | 2023-02-17 | 豪夫迈·罗氏有限公司 | 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 |
| EP3400241B1 (en) * | 2016-01-06 | 2020-07-22 | Outlook Therapeutics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
| JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル－ドラッグ－ディベロップメント－バイオテック | 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療 |
| KR20200135781A (ko) * | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
| MX2020013036A (es) | 2018-06-05 | 2021-02-26 | Amgen Inc | Modulacion de la fagocitosis celular dependiente de anticuerpos. |
| KR102596303B1 (ko) * | 2018-08-29 | 2023-10-30 | 유나이티드 바이오파마, 인크. | 비푸코실화된 항체 및 그의 제조법 |
| CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| EP3941944A4 (en) | 2019-03-20 | 2022-11-30 | The Regents of the University of California | Claudin-6 bispecific antibodies |
| DK3941946T3 (da) | 2019-03-20 | 2025-03-24 | Univ California | Claudin-6-antistoffer og lægemiddelkonjugater |
| WO2020227726A1 (en) | 2019-05-06 | 2020-11-12 | Amgen Inc. | Modulating antibody effector functions |
| MX2022003461A (es) * | 2019-09-26 | 2022-04-19 | Amgen Inc | Metodos de produccion de composiciones de anticuerpos. |
| US20240092935A1 (en) * | 2019-10-11 | 2024-03-21 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| AU2021299338A1 (en) * | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CA3227687A1 (en) * | 2021-08-06 | 2023-02-09 | Marc Andrew GILLIG | Process for producing personalized cancer immunotherapy |
| KR102890992B1 (ko) * | 2023-01-26 | 2025-12-02 | 팔라디바이오텍 주식회사 | 물질의 세포막 파괴 활성을 확인하는데 사용하기 위한 조성물, 및 그의 용도 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| AU762382B2 (en) | 1998-09-29 | 2003-06-26 | Pioneer Hi-Bred International, Inc. | MAR/SAR elements flanking RSYN7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| AU2002216443A1 (en) | 2000-12-15 | 2002-06-24 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region fointerferon beta |
| ES2330201T3 (es) | 2001-01-26 | 2009-12-07 | Selexis S.A. | Regiones de union a la matriz y metodos para el uso de las mismas. |
| US20030157108A1 (en) * | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
| EP1888638A2 (en) * | 2005-06-03 | 2008-02-20 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| EP1921090B1 (en) * | 2005-07-22 | 2015-01-14 | Kyowa Hakko Kirin Co., Ltd. | Genetically modified antibody composition |
| EP2084188A2 (en) * | 2006-10-12 | 2009-08-05 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
| BRPI1010035A2 (pt) * | 2009-06-02 | 2015-08-25 | Regeneron Pharma | Células deficientes em fucosilação |
| EP2438185A4 (en) * | 2009-06-05 | 2016-10-05 | Momenta Pharmaceuticals Inc | METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS |
| WO2012120500A2 (en) * | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| EP3916081A3 (en) * | 2013-08-19 | 2022-03-23 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
| US10752674B2 (en) * | 2014-11-15 | 2020-08-25 | Zumutor Biologics Inc. | DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof |
| JP6587696B2 (ja) * | 2015-05-13 | 2019-10-09 | ズムトール バイオロジクス、インコーポレイテッド | アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法 |
| CN108431026B (zh) | 2015-11-02 | 2023-02-17 | 豪夫迈·罗氏有限公司 | 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法 |
-
2016
- 2016-11-01 CN CN201680077178.3A patent/CN108431026B/zh active Active
- 2016-11-01 EP EP16797693.5A patent/EP3371206B1/en active Active
- 2016-11-01 CA CA2999047A patent/CA2999047A1/en active Pending
- 2016-11-01 SG SG10202103875WA patent/SG10202103875WA/en unknown
- 2016-11-01 ES ES16797693T patent/ES2875274T3/es active Active
- 2016-11-01 CN CN202310074105.0A patent/CN116731147A/zh active Pending
- 2016-11-01 KR KR1020257011036A patent/KR20250051156A/ko active Pending
- 2016-11-01 MX MX2018004831A patent/MX2018004831A/es unknown
- 2016-11-01 WO PCT/US2016/059922 patent/WO2017079165A1/en not_active Ceased
- 2016-11-01 AU AU2016350732A patent/AU2016350732A1/en not_active Abandoned
- 2016-11-01 KR KR1020187009379A patent/KR102793554B1/ko active Active
- 2016-11-01 SG SG11201802773RA patent/SG11201802773RA/en unknown
- 2016-11-01 JP JP2018522671A patent/JP6983772B2/ja active Active
- 2016-11-01 EP EP21162187.5A patent/EP3925970A1/en active Pending
- 2016-11-01 PL PL16797693T patent/PL3371206T3/pl unknown
- 2016-11-01 BR BR112018007356A patent/BR112018007356A2/pt not_active Application Discontinuation
-
2018
- 2018-03-15 IL IL258161A patent/IL258161B2/en unknown
- 2018-05-01 US US15/968,214 patent/US10975168B2/en active Active
-
2021
- 2021-01-13 US US17/148,456 patent/US11802165B2/en active Active
-
2022
- 2022-04-13 AU AU2022202460A patent/AU2022202460A1/en not_active Abandoned
-
2023
- 2023-09-25 US US18/474,014 patent/US12391769B2/en active Active
-
2025
- 2025-07-16 US US19/271,568 patent/US20260042866A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505164A5 (enExample) | ||
| JP2016104045A5 (enExample) | ||
| Dinnis et al. | Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? | |
| JP5592258B2 (ja) | 製造方法 | |
| JP2012065652A5 (enExample) | ||
| JP2019523221A5 (enExample) | ||
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| JP2015525572A5 (enExample) | ||
| SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
| EA201791633A1 (ru) | Способ точной модификации растения посредством транзиентной экспрессии гена | |
| JP2019514383A5 (enExample) | ||
| PH12014500640A1 (en) | Increasing virus-like particle yield in plants | |
| JP2016513478A5 (enExample) | ||
| JP2016513457A5 (enExample) | ||
| CR20200507A (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| Fischer et al. | CHO cell engineering for improved process performance and product quality | |
| RU2017101195A (ru) | Способы культивирования клеток и среды, предусматривающие n-ацетилцистеин | |
| Shin et al. | Efficient CRISPR/Cas9-mediated multiplex genome editing in CHO cells via high-level sgRNA-Cas9 complex | |
| JP7416745B2 (ja) | 改変細胞、調製方法、及び構築物 | |
| Park et al. | Effects of palindrome structure on Dhfr amplification in Chinese hamster ovary cells | |
| CN120752253A (zh) | 具有经优化宿主细胞蛋白谱的cho细胞 | |
| EP4688829A2 (en) | Cho cells with optimized ecm profile | |
| Bolander et al. | Pre-culture and BMP-2 stimulation under serum free conditions enhance proliferation, osteochondrogenic differentiation and BMP-signalling in human periosteum-derived cells | |
| 鄭宏宇 | Dihydrofolate Reductase-Mir-30 RNA based Interference for chimeric antibody expression in CHO cells | |
| Chen et al. | Correction: Hu antigen R and tristetraprolin: Counter‐regulators of rat apical sodium‐dependent bile acid transporter by way of effects on messenger RNA stability |